Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.
Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease
David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.